Physician profile
Vanessa Rojas
NPI 1922498716
$50,131.91
in general payments reported to CMS, 2019-2025
17 companies · $19K in 2025
The $19K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $161 · 2021: $127 · 2022: $2,067 · 2023: $15K · 2024: $13K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $7,244 · Travel and Lodging: $3,984 · Consulting Fee: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,670.00 |
| Food and Beverage | $7,244.05 |
| Travel and Lodging | $3,984.29 |
| Consulting Fee | $2,810.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $45,346.57 | 2019-2025 | Biktarvy, Descovy |
| Viiv Healthcare Company | $3,022.41 | 2019-2025 | Dovato, Apretude, Rukobia |
| Theratechnologies INC. | $597.00 | 2023-2025 | Trogarzo, Egrifta |
| Merck Sharp & Dohme LLC | $336.42 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $189.92 | 2019-2023 | Symtuza |
| Emd Serono, INC. | $112.78 | 2024 | |
| Lilly USA, LLC | $105.13 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $76.94 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $69.30 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $66.65 | 2023 | Quviviq |
| Novo Nordisk INC | $45.40 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.76 | 2022 | |
| Cranial Technologies, INC | $43.44 | 2019-2022 | |
| Glaxosmithkline, LLC. | $24.70 | 2020 | |
| Napo Pharmaceuticals INC | $21.88 | 2025 | Mytesi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.00 | 2019 | |
| Conmed Corporation | $13.61 | 2024 | Conmed Dilation, Conmed Hemostasis, Conmed Biliary |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vanessa Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.